	US 11,696,902 B2
	Method of initiating and escalating sotalol hydrochloride dosing
John Somberg, Chicago, IL (US); Brandon Ira Kashfian, Chicago, IL (US); and Janos Molnar, Chicago, IL (US)
Assigned to AltaThera Pharmaceuticals, LLC, Chicago, IL (US)
Filed by AltaThera Pharmaceuticals LLC, Chicago, IL (US)
Filed on Nov. 24, 2019, as Appl. No. 16/693,310.
Application 16/693,310 is a continuation in part of application No. 16/103,815, filed on Aug. 14, 2018, granted, now 10,512,620.
Prior Publication US 2020/0093759 A1, Mar. 26, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/136 (2006.01); A61K 9/19 (2006.01); A61K 9/00 (2006.01)

CPC A61K 31/136 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01)]

5 Claims

1. A method of initiating oral sotalol hydrochloride therapy comprising:

identifying a subject as naïve to sotalol, having symptomatic atrial fibrillation or atrial flutter, and currently in sinus rhythm;

administering to the subject a single intravenous (IV) dosage of sotalol hydrochloride, over a period of 1 hour, wherein the single IV dosage comprises an amount of sotalol hydrochloride in the range of 116-141 mg;

after completion of the single IV dosage of sotalol hydrochloride, administering a first oral dosage of sotalol hydrochloride in the amount of 120 mg.